Gain Therapeutics
Gain Therapeutics develops allosteric small molecule therapies for disorders with high unmet medical need, specifically targeting neurodegenerative diseases. The company utilizes its Magellan drug discovery platform, which combines AI-supported 3D structural biology with physics-based models to identify novel binding sites on proteins. Its lead drug candidate, GT-02287, is currently in clinical development for the treatment of GBA-Parkinson’s disease.
Healthcare
Biotechnology
Pharmaceuticals
Funding summary
- Total raised
- €2.5M
- Funding rounds
- 1
Investors in Gain Therapeutics
Investors on record for Gain Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Gain Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors